CAR-NK cell therapy: promise and challenges in solid tumors

Over the past few years, cellular immunotherapy has emerged as a promising treatment for certain hematologic cancers, with various CAR-T therapies now widely used in clinical settings. However, challenges related to the production of autologous cell products and the management of CAR-T cell toxicity highlight the need for new cell therapy options that are universal, safe, and effective. Natural killer (NK) cells, which are part of the innate immune system, offer unique advantages, including the potential for off-the-shelf therapy. A recent first-in-human trial of CD19-CAR-NK infusion in patients with relapsed/refractory lymphoid malignancies demonstrated safety and promising clinical activity. Building on these positive clinical outcomes, current research focuses on enhancing CAR-NK cell potency by increasing their in vivo persistence and addressing functional exhaustion. There is also growing interest in applying the successes seen in hematologic malignancies to solid tumors. This review discusses current trends and emerging concepts in the engineering of next-generation CAR- NK therapies. It will cover the process of constructing CAR-NK cells, potential targets for their manufacturing, and their role in various solid tumors. Additionally, it will examine the mechanisms of action and the research status of CAR-NK therapies in the treatment of solid tumors, along with their advantages, limitations, and future challenges. The insights provided may guide future investigations aimed at optimizing CAR-NK therapy for a broader range of malignancies.

• Publication year

  2025

• Venue

  Frontiers in Immunology

• Publication date

  2025-04-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fimmu.2025.1574742PMID 40260240PMCID 12009813
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Emerging Novel Combined CAR-NK Cell Therapies in Cancer Treatment: Finding a Dancing Partner.

  2025cited by this paper
• CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges

  2024cited by this paper
• Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapy

  2024cited by this paper
• Natural killer cell memory: challenges and opportunities for cancer immunotherapy

  2024cited by this paper
• Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy

  2024cited by this paper
• Car T Cells in Solid Tumors: Overcoming Obstacles

  2024cited by this paper
• Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions

  2024cited by this paper
• Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors.

  2024cited by this paper
• Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside

  2024cited by this paper
• Breakthrough of solid tumor treatment: CAR-NK immunotherapy

  2024cited by this paper
• Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?

  2024cited by this paper
• Natural killer cell therapies

  2024cited by this paper
• CAR-NK cells in combination therapy against cancer: A potential paradigm

  2024cited by this paper
• NK Cells in Cancer: Mechanisms of Dysfunction and Therapeutic Potential

  2023cited by this paper
• Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy

  2023cited by this paper
• NK cells are never alone: crosstalk and communication in tumour microenvironments

  2023cited by this paper
• The application of autologous cancer immunotherapies in the age of memory-NK cells

  2023cited by this paper
• Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy

  2023cited by this paper
• Challenges and new technologies in adoptive cell therapy

  2023cited by this paper
• Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect in vivo

  2023cited by this paper
• CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

  2023cited by this paper
• The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy

  2023cited by this paper
• Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint

  2022cited by this paper
• Engineering builds multipotency for iPSC-NKs.

  2022cited by this paper
• Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials

  2022cited by this paper
• Carrier-free multifunctional nanomedicine for intraperitoneal disseminated ovarian cancer therapy

  2022cited by this paper
• CAR NK‐92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo

  2022cited by this paper
• Advances in NK cell production

  2022cited by this paper
• Natural killer cells in antitumour adoptive cell immunotherapy

  2022cited by this paper
• CAR T Cell Locomotion in Solid Tumor Microenvironment

  2022cited by this paper
• Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia

  2022cited by this paper
• Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression

  2022cited by this paper
• Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report

  2022cited by this paper
• NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells

  2022cited by this paper
• Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy

  2022cited by this paper
• CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities

  2022cited by this paper
• Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells

  2022cited by this paper
• Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice

  2022cited by this paper
• Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy

  2022cited by this paper
• Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy

  2022cited by this paper
• Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies

  2022cited by this paper
• Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells.

  2021cited by this paper
• Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors

  2021cited by this paper
• CAR-NK Cells: From Natural Basis to Design for Kill

  2021cited by this paper
• Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells

  2021cited by this paper
• NK Cell-Mediated Eradication of Ovarian Cancer Cells with a Novel Chimeric Antigen Receptor Directed against CD44

  2021cited by this paper
• Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer

  2021cited by this paper
• Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors

  2021cited by this paper
• Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies

  2021cited by this paper
• PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB “Super-Stimulation”

  2021cited by this paper
• CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model

  2021cited by this paper
• Telomerase Reverse Transcriptase Increases Proliferation and Lifespan of Human NK Cells without Immortalization

  2021cited by this paper
• Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe

  2021cited by this paper
• CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy

  2021cited by this paper
• An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma

  2021cited by this paper
• Adoptive Cell Therapy

  2021cited by this paper
• Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

  2021cited by this paper
• Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion

  2021cited by this paper
• Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation.

  2021cited by this paper
• Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT

  2021cited by this paper
• Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy

  2021cited by this paper
• Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries.

  2021cited by this paper
• Arrested development: suppression of NK cell function in the tumor microenvironment

  2021cited by this paper
• Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities

  2021cited by this paper
• Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer

  2020cited by this paper
• CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide

  2020cited by this paper
• Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

  2020cited by this paper
• Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy

  2020cited by this paper
• Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy

  2020cited by this paper
• Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer.

  2020cited by this paper
• Prospects and challenges for use of CAR T cell therapies in solid tumors

  2020cited by this paper
• Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer

  2020cited by this paper
• Design and Characterization of an “All-in-One” Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible Cytokines

  2020cited by this paper
• Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.

  2020influential reference
• Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.

  2020cited by this paper
• Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?

  2020cited by this paper
• High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia

  2020cited by this paper
• The therapeutic landscape for cells engineered with chimeric antigen receptors

  2020cited by this paper
• NK cells for cancer immunotherapy

  2020cited by this paper
• Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer

  2020cited by this paper
• Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

  2020cited by this paper
• Robo1-specific chimeric antigen receptor natural killer cell therapy for pancreatic ductal adenocarcinoma with liver metastasis

  2020cited by this paper
• Chimeric antigen receptor signaling: Functional consequences and design implications

  2020cited by this paper
• Genetically modified immune cells targeting tumor antigens.

  2020cited by this paper
• Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy

  2020cited by this paper
• Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.

  2020cited by this paper
• Targeting epidermal growth factor‐overexpressing triple‐negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor

  2020cited by this paper
• Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment.

  2020cited by this paper
• Acute life-threatening toxicity from CAR T-cell therapy

  2020cited by this paper
• Corrigendum to “Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models”

  2019cited by this paper
• ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

  2019cited by this paper
• Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer

  2019cited by this paper
• The NKG2A immune checkpoint — a new direction in cancer immunotherapy

  2019cited by this paper
• Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines

  2019cited by this paper
• Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.

  2019cited by this paper
• Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy

  2019cited by this paper
• Gene editing for immune cell therapies

  2019cited by this paper
• Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy

  2019cited by this paper
• Target selection for CAR-T therapy

  2019cited by this paper
• Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control

  2019cited by this paper

• Emerging potential of CAR-NK cell therapy for hepatocellular carcinoma: current advances and translational challenges

  2026cites this paper
• CAR-engineered cell therapies: current understandings and future perspectives

  2026cites this paper
• Advances in chimeric antigen receptor-natural killer cell therapy: from mechanisms and preclinical studies to clinical application

  2026cites this paper
• A Novel Natural Killer Cell Expansion Technology for the Development of Cellular Immunotherapies

  2026cites this paper
• NK Cells Engineered with a Chimeric Antigen Receptor Delay HIV Rebound and Reshape HIV Reservoir Composition

  2026cites this paper
• Advances in Next-Generation Immunotherapies for Ovarian Cancer: Mechanisms of Immune Evasion and Novel Therapeutic Targets.

  2026cites this paper
• Advancements and challenges in CAR-NK cell therapy for cancer treatment.

  2026cites this paper
• From innate immunity to precision cancer therapy: the clinical advancement of NK cell therapy.

  2026cites this paper
• Lipid nanoparticle-mediated in vivo generation of panCAR immune cells for solid tumor immunotherapy.

  2026cites this paper
• Innate-like T Cell Biology in the Tumor Microenvironment Implications for Cancer Immunotherapy

  2026cites this paper
• Engineering of Humanized PSMA-Directed CAR T Cells for Potent and Specific Elimination of Prostate Cancer Cells

  2025cites this paper
• Dysfunction of natural killer cells promotes immune escape and disease progression in endometriosis

  2025cites this paper
• Bio-Functional Nanomaterials for Enhanced Lung Cancer Therapy: The Synergistic Roles of Vitamins D and K

  2025cites this paper
• CAR-T and CAR-NK cell therapies in AML: breaking barriers and charting the future

  2025cites this paper
• Mitochondrial priming in therapy-induced senescence: implications for CAR-T/NK immunosenolytic therapy

  2025cites this paper
• The intersection of CAR-T immunotherapy with emerging technologies.

  2025cites this paper
• Exploring CAR NK-cell therapy for refractory lupus.

  2025cites this paper
• Strategies for the Development of NK Cell-Based Therapies for Cancer Treatment

  2025cites this paper
• Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells

  2025cites this paper
• Engineered macrophages accumulate in solid tumors and locally deliver immune-activating proteins to inhibit tumor progression

  2025cites this paper
• Natural Killer (NK) Cell-Based Therapies Have the Potential to Treat Ovarian Cancer Effectively by Targeting Diverse Tumor Populations and Reducing the Risk of Recurrence

  2025cites this paper
• Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies

  2025cites this paper
• 2B4 co-stimulation and dasatinib modulation enhance anti-CD19 CAR-NK-92 cell cytotoxicity

  2025cites this paper
• Engineering CAR T NK and NKT cell therapies to target cancer stem cells and overcome stem like resistance

  2025cites this paper
• Exosomal circRNAs in hepatocellular carcinoma: Implications for the development and therapeutic resistance of hepatocellular carcinoma (Review)

  2025cites this paper
• CAR-NK Engineering to Overcome TME Barriers

  2025cites this paper
• Targeting the Tumor Microenvironment with Gene-Engineered Immune Cells: Focus on CAR-Macrophages and CAR-NK Cells – A Review Article

  2025influential citation
• A new era in CAR-NK cell therapy: from technological innovations to clinical applications

  2025cites this paper
• Targets for CAR Therapy in Multiple Myeloma

  2025cites this paper
• Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives

  2025cites this paper
• Harnessing the chimeric antigen receptor engineered cells in gastrointestinal cancer immunotherapy.

  2025cites this paper
• Imunoterapia por Receptores de Antígenos Quiméricos (CARs) para células Assassinas Naturais (NK), abordagens terapêuticas e perspectivas futuras na área oncológica: uma revisão sistemática de Síntese Sem Metanálise (SWIM)

  2025cites this paper
• Clinical trials of nanoparticle-enhanced CAR-T and NK cell therapies in oncology: overcoming translational and clinical challenges - a mini review

  2025cites this paper
• Beyond CAR-T: Engineered NK cell therapies (CAR-NK, NKCEs) in next-generation cancer immunotherapy.

  2025cites this paper
• PSCA-CAR-NK cells exert cytotoxic activity against PSCA-expressing tumor cells and are characterized by a specific chemokine profile.

  2025cites this paper
• Cytokine Networks in Triple-Negative Breast Cancer: Mechanisms, Therapeutic Targets, and Emerging Strategies

  2025cites this paper
• Laminarihexaose of U. Pinnatifida (Harvey) Suringar exerts anticancer effects by activating natural killer cells

  2025cites this paper